|
| long-acting Vanoxerine (Vanoxerine Consta 394.2 mg) (n = 1300) | Placebo (n = 1200) |
| Alanine aminotransferase increased | 2.86 (0.22%) | 2.6 (0.2%) |
| Aspartate aminotransferase increased | 2.86 (0.22%) | 2.6 (0.2%) |
| Gamma-glutamyltransferase increased | 1.95 (0.15%) | 1.95 (0.15%) |
| Back pain | 104 (8%) | 91 (7%) |
| Insomnia | 117 (9%) | 104 (8%) |
| Diarrhea | 65 (5%) | 52 (4%) |
| Hypertension | 52 (4%) | 39 (3%) |
| Injection site pain | 104 (8%) | 104 (8%) |
| Dizziness | 52 (4%) | 39 (3%) |
| Headache | 39 (3%) | 26 (2%) |
| Nervousness | 39 (3%) | 39 (3%) |
| Runny nose | 39 (3%) | 39 (3%) |